Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last ¥1,338 JPY
Change Today -11.00 / -0.82%
Volume 1.9M
4506 On Other Exchanges
As of 2:00 AM 07/1/15 All times are local (Market data is delayed by at least 15 minutes).

sumitomo dainippon pharma co (4506) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/9/15 - ¥1,625
52 Week Low
12/17/14 - ¥1,132
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SUMITOMO DAINIPPON PHARMA CO (4506)

Related News

No related news articles were found.

sumitomo dainippon pharma co (4506) Related Businessweek News

No Related Businessweek News Found

sumitomo dainippon pharma co (4506) Details

Sumitomo Dainippon Pharma Co., Ltd. manufactures and sells pharmaceuticals, food ingredients, food additives, veterinary medicines, diagnostics, and others in Japan, China, North America, and other regions. The company offers pharmaceutical products, such as therapeutic agents for hypertension, angina pectoris, arrhythmia, Parkinson’s disease, systemic fungal infections, and hepatocellular carcinoma; atypical antipsychotics; antidepressants; rapid-acting insulin secretagogues; vasodilators; and biguanide oral hypoglycemic drugs. It also provides products for therapeutic indications, such as Anderson-Fabry disease, anti-hypertension, gastroprokines, carbapenem antibiotics, sedative hypnotics, short-acting and long-acting beta-agonist, inhaled corticosteroid, corticosteroid nasal spray, and serotonin-agonist antianxiety drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, seasonings, and sweeteners; and chemical product materials, such as cosmetic and coating materials, active pharmaceutical ingredients, and electronic chemicals. Further, it offers veterinary medicines for companion animals, including dogs and cats; and farm animals, such as cattle, swine, horses, and cultured fish. Additionally, the company develops point-of-care testing diagnostic products for infectious diseases and acute myocardial infarctions; in-vitro diagnostics for bone and calcium metabolism, and central nervous system disorders; research materials that facilitate research related to medical care; and BBI608 and BBI503 anticancer drug candidates. It has a joint development agreement with Healios K.K. to develop iPS cell-derived retinal pigment epithelial cells for the treatment of age-related macular degeneration and other eye diseases. The company was formerly known as Dainippon Sumitomo Pharma Co., Ltd. and changed its name to Sumitomo Dainippon Pharma Co., Ltd. in June 2014. The company was founded in 1897 and is headquartered in Osaka, Japan.

6,868 Employees
Last Reported Date: 06/19/15
Founded in 1897

sumitomo dainippon pharma co (4506) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

sumitomo dainippon pharma co (4506) Key Developments

Sumitomo Dainippon Pharma Co., Ltd. Announces Executive Appointments Effective August 1, 2015

Sumitomo Dainippon Pharma Co., Ltd. announced the appointment of Masayo Tada as representative Director, President and Chief Executive Officer, Executive Director, Drug Development from his current post Representative Director, President and Chief Executive Officer effective August 1, 2015; Nobuyuki Hara appointed as Executive Officer Deputy Executive Director, Drug Development from his current post Executive Officer, Executive Director, Drug Development effective August 1, 2015; Teruya Murata appointed as Director, Project Management from his current post Senior Advisor, Drug Development effective August 1, 2015; Hideo Tomiya appointed as Director, Data Science from his current post Deputy Executive Director, Drug Development, Director, Project Management effective August 1, 2015; and Kenji Shirakura appointed as Director, Clinical Operation from his current post Group Manager, Clinical Pharmacology Group, Clinical Research effective August 1, 2015.

JCR Pharmaceuticals Co., Ltd. and Sumitomo Dainippon Pharma Co., Ltd. Conclude Feasibility Study Agreement on Application of the Blood-Brain Barrier Penetration Technology in Psychiatry and Neurology Area

JCR Pharmaceuticals Co., Ltd. and Sumitomo Dainippon Pharma Co., Ltd. jointly announced that the two companies executed on June 17, 2015 a feasibility study agreement under which they will study the feasibility of applying JCR's proprietary blood-brain barrier (BBB) penetration technology "J-Brain Cargo" to discovery of new treatment in the psychiatry and neurology area. Under the terms of the agreement, JCR and Sumitomo Dainippon Pharma will perform collaborative research using the J-Brain Cargo technology and certain pharmaceutical candidate compounds of Sumitomo Dainippon Pharma's choice, with a view to creating innovative pharmaceutical products in psychiatry and neurology area, where high unmet medical needs exist. J-Brain Cargo enables delivery of target substances across the BBB through a certain receptor expressed on the surface of vascular endothelial cells. JCR study confirmed BBB penetration of J-Brain Cargo combined target substance as 20 to 100 times the target substance alone. It is an innovative technology which will provide pharmaceutical compounds of low to high molecules with the capacity to pass through the BBB. A substantially large portion of the pharmaceutical injected intravenously should be able to reach inside the brain and show its efficacy. Significant improvements are expected for psychiatric or neurological disorders for which little improvements have been possible. Financial impacts of the conclusion of the agreement is minor on the consolidated performance for the year ending on March 31, 2016 of either company.

Sumitomo Dainippon Pharma Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ended Mar. 31, 2016; Announces an Year End Dividend for the Fiscal Year Ended Mar. 31, 2015, Payable on June 22, 2015

Sumitomo Dainippon Pharma Co., Ltd. provided dividend guidance for the fiscal year ended Mar. 31, 2016. For the year, the company expects to pay a dividend of ¥9 per share at the end of the second quarter and ¥9 per share at the end of the year, making a total dividend of ¥18 per share for fiscal 2015 against the same amount of dividend for the last year. The company also announced an year end dividend of ¥9 per share for the fiscal year ended Mar. 31, 2015. Starting date of dividend payments is June 22, 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4506:JP ¥1,338.00 JPY -11.00

4506 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Albany Molecular Research Inc $19.85 USD -0.366
Eastman Kodak Co $16.42 USD -0.38
FUJIFILM Holdings Corp ¥4,454 JPY +80.50
GlaxoSmithKline Consumer Nigeria PLC 44.00 NGN 0.00
Pernix Therapeutics Holdings Inc $5.98 USD +0.06
View Industry Companies

Industry Analysis


Industry Average

Valuation 4506 Industry Range
Price/Earnings 34.0x
Price/Sales 1.4x
Price/Book 1.2x
Price/Cash Flow 25.6x
TEV/Sales 0.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SUMITOMO DAINIPPON PHARMA CO, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at